These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37857707)

  • 1. Medication profiling in women with type 1 diabetes highlights the importance of adequate, guideline-based treatment in low-risk groups.
    Lithovius R; Mutter S; Parente EB; Mäkinen VP; Valo E; Harjutsalo V; Groop PH
    Sci Rep; 2023 Oct; 13(1):17893. PubMed ID: 37857707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
    Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA
    Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial.
    Sinha MD; Gu H; Douiri A; Cansick J; Finlay E; Gilbert R; Kerecuk L; Lunn A; Maxwell H; Morgan H; Shenoy M; Shroff R; Subramaniam P; Tizard J; Tse Y; Rezavi R; Simpson JM; Chowienczyk PJ;
    Lancet Child Adolesc Health; 2023 Jan; 7(1):26-36. PubMed ID: 36442482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
    Nicholas SB; Daratha KB; Alicic RZ; Jones CR; Kornowske LM; Neumiller JJ; Fatoba ST; Kong SX; Singh R; Norris KC; Tuttle KR
    Diabetes Obes Metab; 2023 Oct; 25(10):2970-2979. PubMed ID: 37395334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic records suggest suboptimal management of chronic kidney disease in general practice.
    Pilotto LS; Ball PA; Smithard JM; Kennedy DR
    Aust J Rural Health; 2012 Aug; 20(4):195-9. PubMed ID: 22827427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J; Kanno Y; Suzuki H
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
    Hsu CY; Liu KD; Yang J; Glidden DV; Tan TC; Pravoverov L; Zheng S; Go AS
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):26-34. PubMed ID: 31843974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
    Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.